Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QLC7401 PK/PD Bridging Study
NCT07074236Phase 1Not yet recruiting
- Sponsor
- Qilu Pharmaceutical
- Start
- Jul 2025
- Primary completion
- Jan 2026
- Modality
- Conjugated siRNA, Peptide-Drug Conjugates, Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of rbd7022 in hypercholesterolemia and combined hyperlipidemia (2 arms), sponsored by Qilu Pharmaceutical. Primary endpoints: Maximum Plasma Concentration at 48 hours, Area Under the Curve at 48 hours and 4 more. Planned start Jul 2025; status: not yet recruiting.
02
Drugs
rbd7022
03
Conditions
hypercholesterolemiacombined hyperlipidemia
Beyond the preview
Go deeper on NCT07074236.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07074236.